Anti PD-L1 Durvalumab Combined With Cetuximab and Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: a Phase I/II Study
Latest Information Update: 01 Dec 2022
At a glance
- Drugs Cetuximab (Primary) ; Durvalumab (Primary)
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms DUCRO
- 28 Oct 2022 Results evaluating the immunological profile and to investigating the dynamics of cytokine production in peripheral blood mononuclear cells, presented at the 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics
- 01 Apr 2022 Status changed from recruiting to discontinued, as per Results published in the Radiotherapy and Oncology
- 01 Apr 2022 Results published in the Radiotherapy and Oncology